Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors-Reference-Cited by-同舟云学术

Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors

Published:2022-05-01 Issue:5 Volume:147 Page:518-524
ISSN:1543-2165
Container-title:Archives of Pathology & Laboratory Medicine
language:en
Short-container-title:

Author:

Ramkissoon Shakti H.¹²,Fernandes Helen³,Lopez-Terrada Dolores H.⁴,Hameed Meera R.⁵,Trembath Dimitri G.⁶,Bridge Julia A.⁷⁸,Lindeman Neal I.⁹,Souers Rhona J.¹⁰,Vasalos Patricia¹¹,Brat Daniel J.¹²,Moncur Joel T.¹³

Affiliation:

1. From Laboratory Oncology, Laboratory Corporation of America, Burlington, North Carolina (Ramkissoon).

2. From the Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina (Ramkissoon).

3. From the Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York (Fernandes).

4. From the Departments of Pathology and Pediatrics, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas (Lopez-Terrada).

5. From the Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York (Hameed).

6. From the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina (Trembath).

7. From the Division of Cytogenetic and Molecular Pathology, ProPath, Dallas, Texas (Bridge).

8. From the Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha (Bridge).

9. From the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Lindeman).

10. From the Biostatistics Department (Souers), College of American Pathologists, Northfield, Illinois

11. From Proficiency Testing (Vasalos), College of American Pathologists, Northfield, Illinois

12. From the Department of Pathology, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Brat)

13. From the Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Moncur).

Abstract

Context.— Integration of molecular data into glioma classification supports diagnostic, prognostic, and therapeutic decision-making; however, testing practices for these informative biomarkers in clinical laboratories remain unclear. Objective.— To examine the prevalence of molecular testing for clinically relevant biomarkers in adult and pediatric gliomas through review of a College of American Pathologists proficiency testing survey prior to the release of the 2021 World Health Organization Classification of Central Nervous System Tumors. Design.— College of American Pathologists proficiency testing 2020 survey results from 96 laboratories performing molecular testing for diffuse gliomas were used to determine the use of testing for molecular biomarkers in gliomas. Results.— The data provide perspective into the testing practices for diffuse gliomas from a broad group of clinical laboratories in 2020. More than 98% of participating laboratories perform testing for glioma biomarkers recognized as diagnostic for specific subtypes, including IDH. More than 60% of laboratories also use molecular markers to differentiate between astrocytic and oligodendroglial lineage tumors, with some laboratories providing more comprehensive analyses, including prognostic biomarkers, such as CDKN2A/B homozygous deletions. Almost all laboratories test for MGMT promoter methylation to identify patients with an increased likelihood of responding to temozolomide. Conclusions.— These findings highlight the state of molecular testing in 2020 for the diagnosis and classification of diffuse gliomas at large academic medical centers. The findings show that comprehensive molecular testing is not universal across clinical laboratories and highlight the gaps between laboratory practices in 2020 and the recommendations in the 2021 World Health Organization Classification of Central Nervous System Tumors.

Publisher

Archives of Pathology and Laboratory Medicine

Subject

Medical Laboratory Technology,General Medicine,Pathology and Forensic Medicine

Link

https://meridian.allenpress.com/aplm/article-pdf/147/5/518/3214907/i1543-2165-147-5-518.pdf

Reference19 articles.

1. Louis DN , Ohgaki,H, Wiestler,OD, CaveneeWK. World Health Organization Histological Classification of Tumours of the Central Nervous System . Lyon, France: International Agency for Research on Cancer;2016.

2. Louis DN , PerryA, WesselingP, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–1251.

3. Louis DN , PerryA, ReifenbergerG, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–820.

4. Brat DJ , AldapeK, ColmanH, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol . 2018;136(5):805–810.

5. Brat DJ , AldapeK, ColmanH, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020;139(3):603–608.